UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study

Journal of acquired immune deficiency syndromes (1999), 2010-03, Vol.53 (3), p.369-377

2010

Volltextzugriff (PDF)

Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors

AIDS (London), 2019-03, Vol.33 (4), p.675-683

2019

Volltextzugriff (PDF)

Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment

AIDS (London), 2012-01, Vol.26 (3), p.303-314

2012

Volltextzugriff (PDF)

Medications as a Potential Source of Exposure to Phthalates in the U.S. Population

Environmental health perspectives, 2009-02, Vol.117 (2), p.185-189

2009

Volltextzugriff (PDF)

Squalenoylation: A generic platform for nanoparticular drug delivery

Journal of controlled release, 2012-07, Vol.161 (2), p.609-618

2012

Volltextzugriff (PDF)

New-onset diabetes in HIV-treated adults: predictors, long-term renal and cardiovascular outcomes

AIDS (London), 2017-07, Vol.31 (11), p.1535-1543

2017

Volltextzugriff (PDF)

Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses

Journal of drug targeting, 2010-06, Vol.18 (5), p.381-388

2010

Volltextzugriff (PDF)

DIDANOSINE RETINAL TOXICITY

Retina (Philadelphia, Pa.), 2016-12, Vol.36 Suppl 1, p.S159

2016

Volltextzugriff (PDF)

An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs

Journal of antimicrobial chemotherapy, 2017-07, Vol.72 (7), p.2075-2082

2017

Volltextzugriff (PDF)

Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection

The New England journal of medicine, 2003-12, Vol.349 (24), p.2293-2303

2003

Volltextzugriff (PDF)

Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery

Nanomedicine, 2008-03, Vol.4 (1), p.41-48

2008

Volltextzugriff (PDF)

Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care

AIDS (London), 2011-01, Vol.25 (2), p.185-195

2011

Volltextzugriff (PDF)

Monolayered multipolymeric buccal films with drug and polymers of opposing solubilities for ARV therapy: Physico-mechanical evaluation and molecular mechanics modelling

International journal of pharmaceutics, 2013-10, Vol.455 (1-2), p.197-212

2013

Volltextzugriff (PDF)

Efavirenz Capsule Sprinkle and Liquid Formulations With Didanosine and Emtricitabine in HIV-1-infected Infants and Children 3 Months to 6 Years of Age: Study AI266-922

The Pediatric infectious disease journal, 2015-12, Vol.34 (12), p.1355-1360

2015

Volltextzugriff (PDF)

Comparison of Four-Drug Regimens and Pairs of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection

The New England journal of medicine, 2003-12, Vol.349 (24), p.2304-2315

2003

Volltextzugriff (PDF)

Didanosine-loaded chitosan microspheres optimized by surface-response methodology: A modified “Maximum Likelihood Classification” approach formulation for reverse transcriptase inhibitors

Biomedicine & pharmacotherapy, 2015-03, Vol.70, p.46-52

2015

Volltextzugriff (PDF)

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

Journal of acquired immune deficiency syndromes (1999), 2003-01, Vol.32 (1), p.18-29

2003

Volltextzugriff (PDF)

Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: In vitro and in vivo evaluation

Acta pharmaceutica (Zagreb, Croatia), 2008-03, Vol.58 (1), p.61-74

2008

Volltextzugriff (PDF)

Combination Anti-HIV Therapy with the Self-Assemblies of an Asymmetric Bolaamphiphilic Zidovudine/Didanosine Prodrug

Molecular pharmaceutics, 2011-06, Vol.8 (3), p.867-876

2011

Volltextzugriff (PDF)

Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa

AIDS (London), 2011-09, Vol.25 (14), p.1727-1735

2011

Volltextzugriff (PDF)

The use of hot and cold high pressure homogenization to enhance the loading capacity and encapsulation efficiency of nanostructured lipid carriers for the hydrophilic antiretroviral drug, didanosine for potential administration to paediatric patients

Pharmaceutical development and technology, 2012-05, Vol.17 (3), p.353-362

2012

Volltextzugriff (PDF)

Novel oleic acid derivatives enhance buccal permeation of didanosine

Drug development and industrial pharmacy, 2014-05, Vol.40 (5), p.657-668

2014

Volltextzugriff (PDF)

Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients

Journal of acquired immune deficiency syndromes (1999), 2010-12, Vol.55 (5), p.606-609

2010

Volltextzugriff (PDF)

Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV

Journal of antimicrobial chemotherapy, 2006-12, Vol.58 (6), p.1299-1302

2006

Volltextzugriff (PDF)

In vitro comparative evaluation of monolayered multipolymeric films embedded with didanosine-loaded solid lipid nanoparticles: a potential buccal drug delivery system for ARV therapy

Drug development and industrial pharmacy, 2014-05, Vol.40 (5), p.669-679

2014

Volltextzugriff (PDF)

1 – 25 von 610

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(454)
Mit Volltextzugriff
(381)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(550)
Didanosine - Administration & Dosage
(526)
Science & Technology
(383)
Aids/hiv
(379)
Life Sciences & Biomedicine
(375)
Hiv Infections - Drug Therapy
(373)
Drug Therapy, Combination
(301)
Male
(283)
Didanosine - Therapeutic Use
(268)
Female
(258)
Anti-Hiv Agents - Administration & Dosage
(250)
Biological And Medical Sciences
(242)
Medical Sciences
(238)
Zidovudine - Administration & Dosage
(232)
Adult
(228)
Infectious Diseases
(212)
Pharmacology. Drug Treatments
(184)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(161)
Antiviral Agents
(161)
Didanosine - Adverse Effects
(156)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(600)
Ovid
(322)
EZB Electronic Journals Library
(304)
Ingenta
(212)
Single Journals
(182)
IngentaConnect Journals
(126)
ScienceDirect
(59)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(53)
Wiley-Blackwell Journals
(47)
Oxford journals
(45)
JSTOR
(45)
Oxford Journals 2020 Medicine
(42)
SAGE Journals Online
(41)
Wiley Online Library
(38)
Springer journals
(34)
Taylor & Francis Current Content Access
(28)
Taylor & Francis Journals Collection
(28)
Taylor & Francis
(26)
BSC - Ebsco (Business Source Ultimate)
(24)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(22)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study

Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors

Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment

Medications as a Potential Source of Exposure to Phthalates in the U.S. Population

Squalenoylation: A generic platform for nanoparticular drug delivery

New-onset diabetes in HIV-treated adults: predictors, long-term renal and cardiovascular outcomes

Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses

DIDANOSINE RETINAL TOXICITY

An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs

Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection

Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery

Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care

Monolayered multipolymeric buccal films with drug and polymers of opposing solubilities for ARV therapy: Physico-mechanical evaluation and molecular mechanics modelling

Efavirenz Capsule Sprinkle and Liquid Formulations With Didanosine and Emtricitabine in HIV-1-infected Infants and Children 3 Months to 6 Years of Age: Study AI266-922

Comparison of Four-Drug Regimens and Pairs of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection

Didanosine-loaded chitosan microspheres optimized by surface-response methodology: A modified “Maximum Likelihood Classification” approach formulation for reverse transcriptase inhibitors

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: In vitro and in vivo evaluation

Combination Anti-HIV Therapy with the Self-Assemblies of an Asymmetric Bolaamphiphilic Zidovudine/Didanosine Prodrug

Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa

The use of hot and cold high pressure homogenization to enhance the loading capacity and encapsulation efficiency of nanostructured lipid carriers for the hydrophilic antiretroviral drug, didanosine for potential administration to paediatric patients

Novel oleic acid derivatives enhance buccal permeation of didanosine

Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients

Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV

In vitro comparative evaluation of monolayered multipolymeric films embedded with didanosine-loaded solid lipid nanoparticles: a potential buccal drug delivery system for ARV therapy

Suchergebnisse filtern